I would wish that a phase 3 wouldn't be needed. Couldn't they grant EUA based on obvious safety and demonstrated efficacy and use the s/c phase 3 as the validation of efficacy. Leronlimab now has shown benefits across the spectrum of the illness. Now it is a matter finding the optimal time to administer with the scope of the illness for maximum benefit. That perfect may be between the two studies, moderate/severe.